Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010

Oct 27, 2010, 05:00 ET from Simcere Pharmaceutical Group

NANJING, China, Oct. 27 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2010 on Thursday, November 11, 2010, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, November 11 at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

United States toll-free:

+1.866.831.6291

International:

+1.617.213.8860

North China toll-free:

10.800.152.1490

South China toll-free:

10.800.130.0399

China toll free / Netcom:

10.800.852.1490

Hong Kong:

+852.3002.1672

Please ask to be connected to Q3 2010 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 18468376

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free:

+1.888.286.8010

International:

+1.617.801.6888

The passcode for replay participants is: 16680817.The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: ir@simcere.com

In Nanjing:

Frank Zhao

Chief Financial Officer

Simcere Pharmaceutical Group

Tel: +86-25-8556-6666 ext 8818

In Beijing:

Ruirui Jiang

Brunswick Group

Tel: +86-10-6566-2256

In the United States:

Kate Tellier

Brunswick Group

Tel: +1-212-333-3810

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852-3512-5000  

SOURCE Simcere Pharmaceutical Group



RELATED LINKS

http://www.simcere.com